Circassia Pharmaceuticals PLC (GB:NIOX)
LSE:NIOX
Top Page
Circassia Pharmaceuticals
(LSE:NIOX)
Select Model
Select Model
Rating:68Neutral
Price Target:
77.00 p
▲(13.24% Upside)
Action:ReiteratedDate:12/07/25
Circassia Pharmaceuticals' overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company's robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a successful market strategy and increased demand for Circassia's products, strengthening its market position.
Negative Factors
Profitability Concerns
Declining net profit margins may indicate challenges in cost management or pricing power, potentially impacting future profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a successful market strategy and increased demand for Circassia's products, strengthening its market position.
Read all positive factors
Circassia Pharmaceuticals (NIOX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£246.58M
Dividend Yield3.4%
Average Volume (3M)773.67K
Price to Earnings (P/E)11.9
Beta (1Y)0.79
Revenue Growth17.95%
EPS Growth-54.68%
CountryUK
Employees91
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding417,939,270
10 Day Avg. Volume814,266
30 Day Avg. Volume773,666
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)4.43
Price to Sales (P/S)6.30
P/FCF Ratio16.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£86.00Price Target Upside26.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)£50.57M
Circassia Pharmaceuticals Business Overview & Revenue Model
Company Description
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that compr...
How the Company Makes Money
Circassia Pharmaceuticals generates revenue primarily through the sale of its NIOX device and related services to healthcare providers and institutions. The company’s business model is centered on selling its diagnostic products to hospitals, clin...
Circassia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.00M | 41.80M | 36.80M | 31.30M | 27.90M | 23.90M |
| Gross Profit | 28.50M | 30.20M | 26.50M | 22.20M | 19.00M | 16.30M |
| EBITDA | 13.70M | 12.20M | 8.60M | 15.20M | 3.10M | -9.10M |
| Net Income | 5.20M | 3.70M | 10.70M | 16.10M | 3.60M | -33.50M |
Balance Sheet | ||||||
| Total Assets | 71.00M | 68.40M | 91.50M | 98.50M | 86.40M | 103.10M |
| Cash, Cash Equivalents and Short-Term Investments | 11.80M | 10.90M | 19.90M | 19.40M | 12.60M | 7.40M |
| Total Debt | 1.20M | 1.50M | 1.10M | 1.00M | 1.30M | 1.60M |
| Total Liabilities | 6.60M | 8.90M | 7.70M | 16.60M | 19.60M | 37.00M |
| Stockholders Equity | 64.40M | 59.50M | 83.80M | 81.90M | 66.80M | 66.10M |
Cash Flow | ||||||
| Free Cash Flow | 18.80M | 16.20M | 11.30M | 6.60M | 1.20M | -24.40M |
| Operating Cash Flow | 18.70M | 17.20M | 11.60M | 6.70M | 1.40M | -23.90M |
| Investing Cash Flow | -1.40M | -1.00M | -300.00K | -100.00K | -200.00K | -500.00K |
| Financing Cash Flow | -26.80M | -25.10M | -10.50M | -500.00K | 4.10M | 4.30M |
Circassia Pharmaceuticals Technical Analysis
Negative
68.00
Price Trends
64.47
Negative
66.69
Negative
68.55
Negative
Market Momentum
-2.22
Positive
25.51
Positive
7.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NIOX, the sentiment is Negative. The current price of 68 is above the 20-day moving average (MA) of 61.49, above the 50-day MA of 64.47, and below the 200-day MA of 68.55, indicating a bearish trend. The MACD of -2.22 indicates Positive momentum. The RSI at 25.51 is Positive, neither overbought nor oversold. The STOCH value of 7.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:NIOX.
Circassia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £73.67M | 18.93 | 66.44% | 8.33% | -3.61% | -6.35% | |
68 Neutral | £246.58M | 11.85 | 8.39% | 3.40% | 17.95% | -54.68% | |
67 Neutral | £105.19M | 15.58 | 8.50% | ― | -1.43% | 28.57% | |
57 Neutral | £120.97M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £664.92M | -9.44 | 227.10% | ― | -0.28% | 22.94% | |
45 Neutral | £18.20M | -2.69 | -58.27% | ― | 37.39% | -126.19% |
* Healthcare Sector Average
GB:NIOX
Circassia Pharmaceuticals
59.00
-12.89
-17.93%
GB:AGY
Allergy Therapeutics
10.50
4.00
61.54%
GB:BVXP
Bioventix
1,400.00
-1,081.41
-43.58%
GB:EKF
EKF Diagnostics Holdings
24.40
1.15
4.95%
GB:DXRX
Diaceutics
143.00
17.00
13.49%
GB:ABDX
Abingdon Health PLC
7.25
0.75
11.54%
Circassia Pharmaceuticals Corporate Events
Regulatory Filings and Compliance
NIOX Updates Total Voting Rights Following Employee Option Exercises
Neutral
Dec 31, 2025
NIOX Group plc has confirmed that as of 31 December 2025 its issued share capital consists of 417,896,847 ordinary shares, each carrying one voting right, with no shares held in treasury. The updated total follows the exercise of employee options ...
Other
NIOX CFO Increases Stake with Share Purchase
Positive
Dec 4, 2025
NIOX Group plc, a company operating in the pharmaceutical industry, announced that its Chief Financial Officer, Sarah Duncan, has purchased 5,522 Ordinary Shares at a price of 70.64 pence per share. This transaction, which took place on December 3...
Business Operations and StrategyDelistings and Listing Changes
NIOX Group Announces Block Listing Application for New Shares
Positive
Nov 26, 2025
NIOX Group plc, a company involved in the healthcare sector, has announced a block listing application for 115,340 ordinary shares on the London Stock Exchange’s AIM market. This move is part of their Save As You Earn Plan 2024, and the shar...
Delistings and Listing ChangesRegulatory Filings and Compliance
NIOX Group Updates Total Voting Rights Following Share Option Exercises
Neutral
Oct 31, 2025
NIOX Group plc announced an update on its total voting rights, revealing that the company’s issued share capital consists of 417,879,117 Ordinary Shares, each with one voting right. This follows the exercise of options by employees over 7,50...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.